Patents Assigned to Hoffmann-La Roche Inc.
  • COMBINATION THERAPY WITH FAP-TARGETED CD40 AGONISTS
    Publication number: 20230340154
    Abstract: The present invention relates to combination therapies employing FAP-targeted CD40 agonists, in particular bispecific antigen binding molecules comprising at least one antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP) and at least one antigen binding domain capable of specific binding to CD40, and radiotherapy.
    Type: Application
    Filed: May 16, 2023
    Publication date: October 26, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Sara Labiano Alminana, Pedro Romero, Genrich Tolstonog, Christine Trumpfheller, Pablo Umana, Marie Catherine Vozenin
  • NEW QUINAZOLINONE DERIVATIVES
    Publication number: 20230331682
    Abstract: The invention relates to a compound of formula (I) Wherein A, L, R1, R2, R3 and R4 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: June 16, 2023
    Publication date: October 19, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Cosimo Dolente, David Stephen Hewings, Daniel Hunziker, Daniela Krummenacher, Piergiorgio Francesco Tommaso Pettazzoni, Fabienne Ricklin, Claus Riemer, Juergen Wichmann
  • TRANSGENIC RABBIT WITH COMMON LIGHT CHAIN
    Publication number: 20230332175
    Abstract: Herein is reported a transgenic vector comprising a humanized light chain locus, wherein said humanized light chain locus comprises (a) a V gene segment derived from human light chain V segment IGKV1-39-01, (b) 3? proximal to said light chain gene segment a promoter, and (c) 5? proximal to said light chain gene segment at least a fragment of the human IGKJ4 J-element.
    Type: Application
    Filed: November 2, 2022
    Publication date: October 19, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventor: Josef Platzer
  • SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION
    Publication number: 20230331715
    Abstract: The present invention provides novel compounds having the general formula: wherein R1 to R3 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: May 18, 2023
    Publication date: October 19, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Xianfeng LIN, Jianping WANG, Hongying YUN, Xiufang ZHENG
  • COMPLEMENT FACTOR BASED AFFINITY CHROMATOGRAPHY
    Publication number: 20230331796
    Abstract: Herein is reported a fusion polypeptide according to formula I (TAG-X1-C1qA-X2-C1qB-X3-C1qC-X4), comprising a fragment of SEQ ID NO: 01 (C1qA), a fragment of SEQ ID NO: 03 (C1qB), a fragment of SEQ ID NO: 05 (C1qC) and optionally a tag (TAG).
    Type: Application
    Filed: June 27, 2022
    Publication date: October 19, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Alexander KNAUPP, Laurent LARIVIERE, Petra RUEGER, Tilman SCHLOTHAUER, Stefan SEEBER
  • METHOD OF DETERMINING A RISK OF MORTALITY OF A CANCER PATIENT, METHOD OF ASSESSING AN ANTI-CANCER THERAPY, METHOD OF SELECTING CANCER PATIENTS FOR TREATMENT
    Publication number: 20230335285
    Abstract: Methods of determining a risk of mortality are disclosed. In one arrangement, the method comprises receiving patient data representing information about a cancer patient. A mathematical model of mortality risk is used to determine the risk of mortality of the cancer patient based on the received patient data. The mathematical model models a relationship determined from training data between the risk of mortality and values of at least 16 model parameters.
    Type: Application
    Filed: May 26, 2021
    Publication date: October 19, 2023
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Dominik RUETTINGER, Anna BAUER-MEHREN, Tim BECKER
  • OLIGONUCLEOTIDES FOR REDUCTION OF PD-L1 EXPRESSION
    Publication number: 20230331837
    Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.
    Type: Application
    Filed: October 7, 2022
    Publication date: October 19, 2023
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Lykke PEDERSEN, Hassan JAVANBAKHT, Malene JACKEROTT, Soren OTTOSEN, Souphalone LUANGSAY
  • Bispecific HER2 antibodies and methods of use
    Patent number: 11787873
    Abstract: The present invention relates to bispecific HER2 antibodies, novel HER2 antibody variants, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: October 17, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Rebecca Croasdale-Wood, Lydia Jasmin Hanisch, Guy Georges, Thomas Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Claudio Sustmann, Pablo Umana
  • Lenticular label for a medical device
    Patent number: 11786667
    Abstract: A lenticular label for attachment to a surface of a medical device to be used in a pre-set orientation is disclosed. The lenticular label has a first face with a lens structure and a second face including a lenticular graphic resulting from a composition of a plurality of images. The images are aligned with the lens structure so that a different visual impression is obtained by changing a viewing angle from which the lenticular graphic is viewed with respect to the first face. The plurality of images includes a compliance image. The lens structure is arranged such that the compliance image is visible by a user when the lenticular label is attached to the medical device and the medical device is in the pre-set orientation. A medical device with such a lenticular label, and methods of use thereof are also disclosed.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: October 17, 2023
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventor: Rémy Kohler
  • Process for the preparation of oligonucleotides using modified oxidation protocol
    Publication number: 20230322843
    Abstract: The invention relates to a process for the production of a mixed P?O/P?S backbone oligonucleotide comprising a selective oxidation of an intermediary phosphite triester compound of formula I into a phosphodiester compound of formula II according to the scheme applying a novel oxidation protocol and to new oxidation solutions.
    Type: Application
    Filed: January 5, 2023
    Publication date: October 12, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Alec FETTES, Achim GEISER, Leonhard JAITZ
  • METHODS FOR TREATING MULTIPLE SCLEROSIS WITH OCRELIZUMAB
    Publication number: 20230322942
    Abstract: The present invention concerns methods for treating multiple sclerosis (MS) in a patient, and an article of manufacture with instructions for such use.
    Type: Application
    Filed: June 22, 2023
    Publication date: October 12, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventor: Marianna MANFRINI
  • NEW ARYL-PYRIDO-PYRIMIDIN-ONE DERIVATIVES
    Publication number: 20230322776
    Abstract: The invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein n, R1, R2, R3, R4 and R5 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: June 16, 2023
    Publication date: October 12, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Cosimo Dolente, David Stephen Hewings, Daniel Hunziker, Erik Jung, Piergiorgio Francesco Tommaso Pettazzoni, Fabienne Ricklin, Claus Riemer, Juergen Wichmann
  • ANTIGEN BINDING RECEPTORS
    Publication number: 20230322950
    Abstract: The present invention generally relates to antigen binding receptors capable of specific binding to an Fc domain comprising the amino acid mutation P329G according to EU numbering. The present invention also relates to T cells, transduced with a antigen binding receptor which is recruited by specifically binding to/interacting with the mutated Fc domain of therapeutic antibodies. Furthermore, the invention relates to a kit comprising the transduced T cells of the invention and/or nucleic acid molecules, vectors encoding the antigen binding receptors of the present invention and tumor targeting antibodies comprising a mutated Fc domain.
    Type: Application
    Filed: January 31, 2023
    Publication date: October 12, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Diana DAROWSKI, Anne FREIMOSER-GRUNDSCHOBER, Christian KLEIN, Ekkehard MOESSNER
  • Antibodies binding to CD3 and CD19
    Patent number: 11780920
    Abstract: The present invention generally relates to antibodies that bind to CD3 and CD19, e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: October 10, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Anne Freimoser-Grundschober, Maria Valeria Gonzalez Nicolini, Ralf Hosse, Alexander Knaupp, Ekkehard Moessner, Wolfgang Richter, Halina Trochanowska, Pablo Umaña, Christian Klein, Inja Waldhauer
  • Bispecific antigen binding molecules targeting OX40 and FAP
    Patent number: 11780919
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising at least two antigen binding domains capable of specific binding to OX40 and a particular antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: October 10, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Juergen Peter Bachl, Alexander Bujotzek, Carina Cantrill, Harald Duerr, Janine Faigle, Sabine Imhof-Jung, Christian Klein, Thomas Kraft, Estelle Marrer-Berger, Ekkehard Moessner, Laurene Pousse, Petra Rueger, Johannes Sam, Roland Staack, Dietrich Tuerck, Pablo Umana, Joerg Zielonka
  • Solid forms of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3- yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use
    Patent number: 11780834
    Abstract: Provided herein are solid forms, salts, and formulations of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol, processes and synthesis thereof, and methods of their use in the treatment of cancer.
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: October 10, 2023
    Assignees: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Cheol Keun Chung, Jie Xu, Hans Iding, Kyle Clagg, Michael Dalziel, Alec Fettes, Francis Gosselin, Ngiap-Kie Lim, Andrew McClory, Haiming Zhang, Paroma Chakravarty, Karthik Nagapudi, Sarah Robinson
  • ASSAYS FOR FIXED DOSE COMBINATIONS
    Publication number: 20230314420
    Abstract: Assays to analyze quality and quantity attributes of fixed dose combinations are provided. In particular, assays for fixed dose combinations of two anti-HER2 antibodies, and for subcutaneous formulations comprising pertuzumab and trastuzumab are described herein.
    Type: Application
    Filed: January 11, 2023
    Publication date: October 5, 2023
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Cécile AVENAL, Nadine HOLZMANN, Michael NOAK, Tania RUCHTY, Gabriele Maria SCHAEFER, Franziska ZAEHRINGER
  • ANTI-HUMAN CD19 ANTIBODIES WITH HIGH AFFINITY
    Publication number: 20230312710
    Abstract: The present invention relates to antibodies against human CD19 (anti-human CD19 antibodies), methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
    Type: Application
    Filed: November 3, 2022
    Publication date: October 5, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Thomas Hofer, Claudia Ferrara Koller, Ekkehard Moessner, Mi He
  • POLYMERS AND USES THEREOF
    Publication number: 20230312837
    Abstract: Disclosed herein are novel copolymers of poly(?-caprolactone) (PCL) and polydopamine (PDA), optionally further comprising a PEG chain, methods for making them as well as their use in pharmaceutical preparations, especially implants or in situ gelling depots, for the treatment of ocular disorders or eye diseases.
    Type: Application
    Filed: June 9, 2023
    Publication date: October 5, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Floriane Bahuon, Jean Coudane, Vincent Darcos, Benjamin Nottelet, Sulabh Pravinchandra Patel, Gregoire Schwach
  • COMBINATION THERAPIES FOR TREATMENT OF HER2 CANCER
    Publication number: 20230310455
    Abstract: Provided are combination therapies comprising inavolisib (a.k.a. GDC-0077) and other HER2-targeted therapies (e.g., pertuzumab and trastuzumab) for the treatment of HER2-positive cancers; and methods of treating HER2 positive (HER2+) cancers in a patient (preferably a patient with a PIK3CA mutant breast cancer) comprising administering a therapeutically effective amount of inavolisib and a HER2-targeted therapy (e.g., trastuzumab, pertuzumab, or a combination of trastuzumab and pertuzumab).
    Type: Application
    Filed: June 9, 2023
    Publication date: October 5, 2023
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Jennifer Lee Schutzman, Chunyan Song, Kyung Wha Song, Eirini Thanopoulou, Simon Peter Warburton, Anwesha Dey, Stephanie Royer Joo